In the TRANSCEND NHL 001 study reported in The Lancet, Jeremy S. Abramson, MD, and colleagues found that the autologous CD19-directed chimeric antigen receptor T-cell agent lisocabtagene maraleucel produced a high response rate in patients with relapsed or refractory large B-cell lymphomas.
Adolescents and young adults (AYAs) with lymphoma are a unique population, with distinct biology, disparities in outcome, poorer survival compared with children and adults, and variable impacts of treatments. Ongoing research on this patient population with lymphoma will hopefully lead to improved understanding of this entity, better therapies, and improved outcomes, according to experts who spoke at the 2020 American Association for Cancer Research (AACR) Virtual Meeting: Advances in Malignant Lymphoma.1-3
Chimeric antigen receptor (CAR) T-cell therapies are a major advance in the treatment of hematologic malignancies and are making inroads in solid tumors, but there is room for improvement in their design, since not all patients respond, and those who do may relapse. Researchers are studying multiple avenues for fine-tuning these therapies to make them more effective and less toxic. At the recent American Association for Cancer Research (AACR) Virtual Meeting: Advances in Malignant Lymphoma, investigators discussed promising strategies for the future.1-3
As reported in the Journal of Clinical Oncology by Knörr et al, a trial of risk-stratified treatment for relapsed pediatric anaplastic large cell lymphoma showed that allogeneic stem cell transplantation (SCT) was effective in patients with high-risk relapse, whereas autologous SCT was not effective in individuals with early relapse.
As reported in the Journal of Clinical Oncology by Pieternella Johanna Lugtenburg, MD, PhD, and colleagues, a phase III trial showed that early rituximab intensification in R-CHOP-14 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) did not improve the rate of complete remission vs standard R-CHOP-14 in patients with diffuse large B-cell lymphoma.